United Kingdom
United Kingdom

Time filter

Source Type

News Article | December 6, 2016
Site: www.businesswire.com

IRVINE, Calif.--(BUSINESS WIRE)--Opus Bank (“Opus” or the “Bank”)) (NASDAQ: OPB) announced today that Frederic Stupart has joined Opus’ Merchant Banking division and Opus Financial Partners, the Bank’s broker-dealer subsidiary, as Managing Director, Financial Sponsors Group. Mr. Stupart, an investment banking and private equity veteran with over 20 years of experience, is responsible for developing and maintaining relationships and providing capital funding, tailored solutions, and strategic advice for middle-market companies and their private equity sponsors. Additionally, Opus announced today that its Merchant Banking division has opened an office in New York City, New York. The new office will support its growing Merchant Banking team in the Northeast. The new office is located in Midtown Manhattan in the Lever House at 390 Park Avenue, 8th Floor, New York City, New York. Stephen H. Gordon, Chairman, CEO & President of Opus Bank, stated, “I am pleased to announce the continued expansion of our Merchant Banking team and the opening of the New York office. We look forward to Fred’s contributions as we expand the capabilities of Opus’ Merchant Banking division, which has more than doubled its revenues year over year.” Gordon added, “With the office in New York City, which is in immediate proximity to investment banks, private equity firms, and mezzanine funds, Opus’ Merchant Banking division is now better positioned to provide its one-stop principal investing and advisory solutions, as well as be a more effective strategic partner to its existing base of financial sponsor relationships and their portfolio companies. The new office will also allow Opus to scale up its Merchant Banking team by accessing the pool of deeply talented and experienced investment bankers/advisors desirous of working in a uniquely entrepreneurial and collaborative environment such as Opus.” Dale Cheney, President of the Merchant Banking Division, continued, “Fred’s successful experience as both a private equity and investment banking professional complements our differentiated merchant banking model of providing a flexible one-stop principal investing and advisory solution to lower middle-market companies. In this effort, Fred will be working closely with financial sponsors to provide growth equity capital for portfolio companies, structure financings for new acquisitions, and present M&A opportunities to the financial sponsor community.” Mr. Stupart, a 21-year investment banking and finance veteran, joins Opus’ Merchant Banking division from Eaglestone Capital Management, LLC in New York City, where he served as Managing Member, Chief Investment Officer and was responsible for originating investment opportunities focused on public market private equity investments. From 2009 to 2012, Mr. Stupart served as Executive Director, Leveraged & Acquisition Finance – Sponsor Coverage at Morgan Stanley in New York, where he led the sponsors coverage effort. From 2008 to 2009, Mr. Stupart served as Principal at EG Capital Group, LLC, where he was responsible for new investment opportunities in the middle market. From 2002 to 2009, Mr. Stupart served as Vice President, Leveraged Finance and Financial Sponsors Coverage at Credit Suisse Securities (USA) LLC, where he developed sponsor relationships while working on debt, equity, and M&A transactions across various industries. Earlier in his career, he served in finance roles with Deutsche Bank AG, Clifford Chance LLP, and Davies, Ward & Beck. Mr. Stupart holds a Bachelor of Arts Honours degree in Economics from Queen’s University in Kingston, Ontario, Canada; a J.D. from Osgoode Hall Law School in Toronto, Ontario, Canada; and an M.B.A. from The Wharton School, University of Pennsylvania. About Opus Bank’s Merchant Banking Division Opus Bank’s Merchant Banking Division is an integrated principal investing and financial advisory platform that provides a broad range of direct investment and advisory solutions to lower middle-market companies. The Merchant Banking Division includes Opus Equity Partners, LLC, the advisor to the Opus Bank-sponsored private equity SBIC Fund that provides growth capital to successful and dynamic companies in need of a capital solution beyond what is customarily available from traditional bank sources. The Merchant Banking Division also includes both Opus Financial Partners, LLC, Opus Bank’s wholly-owned registered broker-dealer and an investment banking group that provide advisory solutions to lower middle-market companies for mergers & acquisitions, leveraged buy-outs, growth equity capital, junior and senior debt, recapitalizations and other broad transactional support to assist companies in their business development efforts. About Opus Bank Opus Bank is an FDIC-insured California-chartered commercial bank with $7.7 billion of total assets, $6.3 billion of total loans and $6.5 billion in total deposits as of September 30, 2016. Opus Bank provides superior ideas and solutions, and banking products to its clients through its Retail Bank, Commercial Bank, Merchant Bank, and Correspondent Bank. Opus Bank offers a suite of treasury and cash management and depository solutions and a wide range of loan products, including commercial, healthcare, media and entertainment, corporate finance, multifamily residential, commercial real estate, and structured finance, and is an SBA preferred lender. Opus Bank offers commercial escrow services and facilitates 1031 Exchange transactions through its Escrow and Exchange divisions. Opus Bank provides clients with financial and advisory services related to raising equity capital, targeted acquisition and divestiture strategies, general mergers and acquisitions, debt and equity financing, balance sheet restructuring, valuation, strategy, and performance improvement through its Merchant Banking Division and its broker-dealer subsidiary, Opus Financial Partners, LLC. Opus Bank’s subsidiary, PENSCO Trust Company, is a leading tech-enabled alternative asset IRA custodian with over $12 billion of custodial assets and over 48,000 client accounts, which are comprised of self-directed investors, financial institutions, capital raisers, and financial advisors. Opus Bank operates 56 banking offices, including 32 in California, 21 in the Seattle/Puget Sound region in Washington, two in the Phoenix metropolitan area of Arizona, and one in Portland, Oregon. Opus Bank is an Equal Housing Lender. For additional information about Opus Bank, please visit our website: www.opusbank.com. Forward-Looking Statements This release may include forward-looking statements related to Opus’ plans, beliefs and goals, which involve certain risks, and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. The forward-looking information presented in this press release is not a guarantee of future events, and actual events may differ materially from those made in or suggested by the forward-looking information contained in this press release. Forward-looking statements generally can be identified by the use of forward-looking terminology such as “intend” or “expect” or variations thereon or similar terminology. All such statements speak only as of the date made, and Opus undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.


DURHAM, N.C., Dec. 13, 2016 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS) (“Argos”), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies based on the Arcelis® precision immunotherapy technology platform, today announced the appointment of Ralph Snyderman, M.D., and Irackly Mtibelishvily, LL.M., to the company's board of directors. “It is a privilege to welcome a pair of profoundly accomplished professionals to the Argos board of directors who offer renowned expertise in each of their respective fields,” said Jeff Abbey, president and CEO of Argos. “Dr. Snyderman is widely referred to as the ‘father of personalized medicine’ and his experience running the Duke University Health System as well as his senior leadership roles at Genentech will help guide us as we advance our individualized immunotherapy through the final stages of clinical development, assess indication expansion and approach our goal of becoming a fully-integrated commercial company. In addition, Irackly Mtibelishvily is globally recognized as one of the most experienced international investment bankers and will advise on important corporate finance and other strategic activities in the years ahead.” Dr. Snyderman is chancellor emeritus at Duke University, James B. Duke professor of medicine, and director of the Center for Research on Personalized Health Care.  He served as chancellor for health affairs and dean of the Duke University School of Medicine from 1989 to 2004.  During this time, he oversaw the development of the Duke University Health System and served as its first president and chief executive officer. Dr. Snyderman has played a leading role in the conception and development of Personalized Health Care, an evolving model of national health care delivery.  Previously, Dr. Snyderman served as senior vice president for medical research and development at Genentech, Inc., the pioneering biomedical technology firm.  He has played a leadership role in important national organizations such as the Association of American Physicians, the National Academy of Medicine, and Association of American Medical Colleges. Dr. Snyderman earned a doctor of medicine degree from SUNY Downstate Medical Center. Mr. Mtibelishvily is currently managing director and chairman of corporate and investment banking in Central and Eastern Europe, the Middle East and Africa for Citigroup, where he has served in various roles for nearly two decades. A specialist in corporate finance, capital markets, securities, and mergers and acquisitions, Mr. Mtibelishvily also has experience working with the multinational law firm Clifford Chance LLP. He earned a master of international legal studies degree from the Moscow State Institute of International Relations and a master of laws degree from the University of Virginia Law School. Dr. Snyderman and Mr. Mtibelishvily will replace vacating Argos directors Philippe Van Holle, M.B.A., and Andrei Petrov, Ph.D. “On behalf of the management team, board of directors and shareholders, I would like to thank Philippe and Andrei for their dedication and support over the last several years,” said Hubert Birner, Ph.D., chairman of the Argos board of directors. “They each have played an instrumental role in the growth and development of Argos.” About the Arcelis® Technology Platform Arcelis® is a precision immunotherapy technology that captures both mutated and variant antigens that are specific to each patient’s individual disease. It is designed to overcome immunosuppression by producing a specifically targeted, durable memory T-cell response without adjuvants that may be associated with toxicity. The technology is potentially applicable to the treatment of a wide range of different cancers and infectious diseases, and is designed to overcome many of the manufacturing and commercialization challenges that have impeded other personalized immunotherapies. The Arcelis® process uses only a small disease sample or biopsy as the source of disease-specific antigens, and the patient’s own dendritic cells, which are optimized from cells collected by a single leukapheresis procedure. The proprietary process uses RNA isolated from the patient's disease sample to program dendritic cells to target disease-specific antigens. These activated, antigen-loaded dendritic cells are then formulated with the patient’s plasma, and administered via intradermal injection as an individualized immunotherapy. About Argos Therapeutics Argos Therapeutics is an immuno-oncology company focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis® technology platform. Argos' most advanced product candidate, AGS-003, is being evaluated in the pivotal ADAPT Phase 3 clinical trial for the treatment of metastatic renal cell carcinoma (mRCC).  In addition, AGS-003 is being studied in Phase 2 investigator-initiated clinical trials as neoadjuvant therapy for renal cell carcinoma (RCC) and for the treatment of non-small cell lung cancer (NSCLC). Argos is also developing a separate Arcelis®-based product candidate, AGS-004, for the treatment of human immunodeficiency virus (HIV), which is currently being evaluated in an investigator-initiated Phase 2 clinical trial aimed at HIV eradication in adult patients. Forward Looking Statements Any statements in this press release about Argos’ future expectations, plans and prospects, including statements about the expected and potential future closings of the private placement, Argos’ financial prospects, anticipated use of proceeds, future operations and sufficiency of funds for future operations, clinical development of Argos’ product candidates, expectations regarding future clinical trials and future expectations and plans and prospects for Argos and other statements containing the words "believes," "anticipates," "estimates," "expects," "intends," "plans," "predicts," "projects," "targets," “may,” "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995.  Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including whether Argos' cash resources will be sufficient to fund its continuing operations for the periods anticipated; whether results obtained in clinical trials will be indicative of results obtained in future clinical trials; whether Argos' product candidates will advance through the clinical trial process on a timely basis; whether the results of such trials will warrant submission for approval from the United States Food and Drug Administration or equivalent foreign regulatory agencies; whether Argos' product candidates will receive approval from regulatory agencies on a timely basis or at all; whether, if product candidates obtain approval, they will be successfully distributed and marketed; and other factors discussed in the "Risk Factors" section of Argos’ Form 10-Q for the quarter ended September 30, 2016, which is on file with the SEC, and in other filings Argos makes with the SEC from time to time. In addition, the forward-looking statements included in this press release represent Argos’ views as of the date hereof. Argos anticipates that subsequent events and developments will cause Argos’ views to change. However, while Argos may elect to update these forward-looking statements at some point in the future, Argos specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Argos’ views as of any date subsequent to the date hereof.


DURHAM, N.C., Dec. 13, 2016 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS) (“Argos”), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies based on the Arcelis® precision immunotherapy technology platform, today announced the appointment of Ralph Snyderman, M.D., and Irackly Mtibelishvily, LL.M., to the company's board of directors. “It is a privilege to welcome a pair of profoundly accomplished professionals to the Argos board of directors who offer renowned expertise in each of their respective fields,” said Jeff Abbey, president and CEO of Argos. “Dr. Snyderman is widely referred to as the ‘father of personalized medicine’ and his experience running the Duke University Health System as well as his senior leadership roles at Genentech will help guide us as we advance our individualized immunotherapy through the final stages of clinical development, assess indication expansion and approach our goal of becoming a fully-integrated commercial company. In addition, Irackly Mtibelishvily is globally recognized as one of the most experienced international investment bankers and will advise on important corporate finance and other strategic activities in the years ahead.” Dr. Snyderman is chancellor emeritus at Duke University, James B. Duke professor of medicine, and director of the Center for Research on Personalized Health Care.  He served as chancellor for health affairs and dean of the Duke University School of Medicine from 1989 to 2004.  During this time, he oversaw the development of the Duke University Health System and served as its first president and chief executive officer. Dr. Snyderman has played a leading role in the conception and development of Personalized Health Care, an evolving model of national health care delivery.  Previously, Dr. Snyderman served as senior vice president for medical research and development at Genentech, Inc., the pioneering biomedical technology firm.  He has played a leadership role in important national organizations such as the Association of American Physicians, the National Academy of Medicine, and Association of American Medical Colleges. Dr. Snyderman earned a doctor of medicine degree from SUNY Downstate Medical Center. Mr. Mtibelishvily is currently managing director and chairman of corporate and investment banking in Central and Eastern Europe, the Middle East and Africa for Citigroup, where he has served in various roles for nearly two decades. A specialist in corporate finance, capital markets, securities, and mergers and acquisitions, Mr. Mtibelishvily also has experience working with the multinational law firm Clifford Chance LLP. He earned a master of international legal studies degree from the Moscow State Institute of International Relations and a master of laws degree from the University of Virginia Law School. Dr. Snyderman and Mr. Mtibelishvily will replace vacating Argos directors Philippe Van Holle, M.B.A., and Andrei Petrov, Ph.D. “On behalf of the management team, board of directors and shareholders, I would like to thank Philippe and Andrei for their dedication and support over the last several years,” said Hubert Birner, Ph.D., chairman of the Argos board of directors. “They each have played an instrumental role in the growth and development of Argos.” About the Arcelis® Technology Platform Arcelis® is a precision immunotherapy technology that captures both mutated and variant antigens that are specific to each patient’s individual disease. It is designed to overcome immunosuppression by producing a specifically targeted, durable memory T-cell response without adjuvants that may be associated with toxicity. The technology is potentially applicable to the treatment of a wide range of different cancers and infectious diseases, and is designed to overcome many of the manufacturing and commercialization challenges that have impeded other personalized immunotherapies. The Arcelis® process uses only a small disease sample or biopsy as the source of disease-specific antigens, and the patient’s own dendritic cells, which are optimized from cells collected by a single leukapheresis procedure. The proprietary process uses RNA isolated from the patient's disease sample to program dendritic cells to target disease-specific antigens. These activated, antigen-loaded dendritic cells are then formulated with the patient’s plasma, and administered via intradermal injection as an individualized immunotherapy. About Argos Therapeutics Argos Therapeutics is an immuno-oncology company focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis® technology platform. Argos' most advanced product candidate, AGS-003, is being evaluated in the pivotal ADAPT Phase 3 clinical trial for the treatment of metastatic renal cell carcinoma (mRCC).  In addition, AGS-003 is being studied in Phase 2 investigator-initiated clinical trials as neoadjuvant therapy for renal cell carcinoma (RCC) and for the treatment of non-small cell lung cancer (NSCLC). Argos is also developing a separate Arcelis®-based product candidate, AGS-004, for the treatment of human immunodeficiency virus (HIV), which is currently being evaluated in an investigator-initiated Phase 2 clinical trial aimed at HIV eradication in adult patients. Forward Looking Statements Any statements in this press release about Argos’ future expectations, plans and prospects, including statements about the expected and potential future closings of the private placement, Argos’ financial prospects, anticipated use of proceeds, future operations and sufficiency of funds for future operations, clinical development of Argos’ product candidates, expectations regarding future clinical trials and future expectations and plans and prospects for Argos and other statements containing the words "believes," "anticipates," "estimates," "expects," "intends," "plans," "predicts," "projects," "targets," “may,” "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995.  Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including whether Argos' cash resources will be sufficient to fund its continuing operations for the periods anticipated; whether results obtained in clinical trials will be indicative of results obtained in future clinical trials; whether Argos' product candidates will advance through the clinical trial process on a timely basis; whether the results of such trials will warrant submission for approval from the United States Food and Drug Administration or equivalent foreign regulatory agencies; whether Argos' product candidates will receive approval from regulatory agencies on a timely basis or at all; whether, if product candidates obtain approval, they will be successfully distributed and marketed; and other factors discussed in the "Risk Factors" section of Argos’ Form 10-Q for the quarter ended September 30, 2016, which is on file with the SEC, and in other filings Argos makes with the SEC from time to time. In addition, the forward-looking statements included in this press release represent Argos’ views as of the date hereof. Argos anticipates that subsequent events and developments will cause Argos’ views to change. However, while Argos may elect to update these forward-looking statements at some point in the future, Argos specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Argos’ views as of any date subsequent to the date hereof.


Dublin, Feb. 15, 2017 (GLOBE NEWSWIRE) -- Research and Markets has announced the addition of the "China Attorney Hourly Rate Report 2017" report to their offering. The "China Attorney Rate Report 2017" is the most comprehensive analysis of the explosive legal market in the People's Republic of China. The growth in legal activity and hourly rates has mirrored the Chinese economy with double-digit growth since 2005. The Report details the hourly rates at major Chinese national Firms as well as non-Chinese Firms trying to make in-roads into the country. China and Asia in general will soon out-strip both the United States and UK legal markets in terms of legal spend, according to the Report. Key Topics Covered: 1: Rates & Projections for the Top 200 2: Individual Firms Rates & Projections 3: Rates & Projections by Practice Area for Top 200 4: Rates & Projections by Cities for the Top 200 5: Rates & Projections by Industries for the Top 200 Companies Mentioned - Akin Gump Strauss Hauer & Feld LLP - Allen & Overy LLP - Appleby Global Group Services Limited - Ashurst LLP - Baker & McKenzie LLP - Campbells - Cleary Gottlieb Steen & Hamilton LLP - Clifford Chance LLP - Covington & Burling LLP - DLA Piper - Dacheng (Dentons) - Davis Polk & Wardwell LLP - De Brauw Blackstone Westbroek - Deacons - Debevoise & Plimpton LLP - Dechert LLP - Fangda Partners - Foley & Lardner LLP - Gibson, Dunn & Crutcher LLP - Greenberg Traurig LLP - Hammonds LLP - Han Kun Law Offices - Herbert Smith Freehills - Hogan Lovells LLP - Ince & Company - Jade & Fountain PRC Lawyers Corporation - Jones Day - K&L Gates LLP - King & Wood Mallesons - Kirkland & Ellis LLP - Latham & Watkins LLP - Linklaters - Loyens & Loeff - Mayer Brown LLP - Milbank, Tweed, Hadley & McCloy LLP - Morgan, Lewis & Bockius LLP - Morrison & Foerster LLP - Mourant Ozannes - Norton Rose Fulbright LLP - Paul Hastings LLP - Reed Smith LLP - Ropes & Gray LLP - Sheppard, Mullin, Richter & Hampton LLP - Sidley Austin LLP - Simpson Thacher & Bartlett LLP - Skadden, Arps, Slate, Meagher & Flom LLP - Steptoe & Johnson LLP - Sullivan & Cromwell LLP - Troutman Sanders LLP - Vinson & Elkins LLP - Weil, Gotshal & Manges LLP - White & Case LLP - Zhong Lun Law Firm For more information about this report visit http://www.researchandmarkets.com/research/flkzph/china_attorney


Dublin, Feb. 15, 2017 (GLOBE NEWSWIRE) -- Research and Markets has announced the addition of the "China Attorney Hourly Rate Report 2017" report to their offering. The "China Attorney Rate Report 2017" is the most comprehensive analysis of the explosive legal market in the People's Republic of China. The growth in legal activity and hourly rates has mirrored the Chinese economy with double-digit growth since 2005. The Report details the hourly rates at major Chinese national Firms as well as non-Chinese Firms trying to make in-roads into the country. China and Asia in general will soon out-strip both the United States and UK legal markets in terms of legal spend, according to the Report. Key Topics Covered: 1: Rates & Projections for the Top 200 2: Individual Firms Rates & Projections 3: Rates & Projections by Practice Area for Top 200 4: Rates & Projections by Cities for the Top 200 5: Rates & Projections by Industries for the Top 200 Companies Mentioned - Akin Gump Strauss Hauer & Feld LLP - Allen & Overy LLP - Appleby Global Group Services Limited - Ashurst LLP - Baker & McKenzie LLP - Campbells - Cleary Gottlieb Steen & Hamilton LLP - Clifford Chance LLP - Covington & Burling LLP - DLA Piper - Dacheng (Dentons) - Davis Polk & Wardwell LLP - De Brauw Blackstone Westbroek - Deacons - Debevoise & Plimpton LLP - Dechert LLP - Fangda Partners - Foley & Lardner LLP - Gibson, Dunn & Crutcher LLP - Greenberg Traurig LLP - Hammonds LLP - Han Kun Law Offices - Herbert Smith Freehills - Hogan Lovells LLP - Ince & Company - Jade & Fountain PRC Lawyers Corporation - Jones Day - K&L Gates LLP - King & Wood Mallesons - Kirkland & Ellis LLP - Latham & Watkins LLP - Linklaters - Loyens & Loeff - Mayer Brown LLP - Milbank, Tweed, Hadley & McCloy LLP - Morgan, Lewis & Bockius LLP - Morrison & Foerster LLP - Mourant Ozannes - Norton Rose Fulbright LLP - Paul Hastings LLP - Reed Smith LLP - Ropes & Gray LLP - Sheppard, Mullin, Richter & Hampton LLP - Sidley Austin LLP - Simpson Thacher & Bartlett LLP - Skadden, Arps, Slate, Meagher & Flom LLP - Steptoe & Johnson LLP - Sullivan & Cromwell LLP - Troutman Sanders LLP - Vinson & Elkins LLP - Weil, Gotshal & Manges LLP - White & Case LLP - Zhong Lun Law Firm For more information about this report visit http://www.researchandmarkets.com/research/flkzph/china_attorney


Dublin, March 02, 2017 (GLOBE NEWSWIRE) -- Research and Markets has announced the addition of the "2017 EU Attorney Rate Report" report to their offering. The 2017 European Union Attorney Hourly Rate Report details the hourly rates charged by Attorneys (Senior Partners, Partners, Counsel, Senior Associates and Associates) from 2011 - 2016 + 2017 Forecast at over 100 individual Law Firms practicing in the 28 Country Union with Germany, the UK and Belgium being the legal engines of growth. The Report has 9 Sections: 1. Overall Rates by Individual Firm, Practice and City 2. Overall Rates by City Consolidated 3. Rates by Industry Consolidated 4. Rates by AMLAW Group (10, 50, 100, 101-200 + Non-AMLAW US Firms) 5. Rates by AMLAW Group by Practice 6. Rates by AMLAW Group by City 7. Rates by AMLAW Group by Industry 8. Overall Rates Magic Circle Firms 9. Rates by Magic Circle Firms Individually 10. Rates by Magic Circle Firms Consolidated by Practice Area The EU economic recovery started much later than that in the United States so growth will continue in 2017 - industrial production is flat, unemployment is down, inflation is flat versus one year ago - as will levels of corporate legal spend and hourly rates charged by EU Attorneys. However, as the threat of a recession in the US grows due to slow economic growth and government debt, the EU faces uncertainty with the BREXIT vote and the highest level of government debt ever (85% of GDP Overall), according to the Report. Key Topics Covered: 1. Overall Rates by Individual Firm, Practice and City 2) Overall Rates by City Consolidated 3. Rates by Industry Consolidated 4. Rates by AMLAW Group (10, 50, 100, 101-200 + Non-AMLAW US Firms) 5. Rates by AMLAW Group by Practice 6) Rates by AMLAW Group by City 7. Rates by AMLAW Group by Industry 8. Overall Rates Magic Circle Firms 9. Rates by Magic Circle Firms Individually 10. Rates by Magic Circle Firms Consolidated by Practice Area Companies Mentioned - Addleshaw Goddard LLP - ADVISES Partnerschaft von Rechtsanwälten, Wirtschaftsprüfern und Steuerberatern - Akin Gump Strauss Hauer & Feld LLP - Allen & Overy LLP - Arnold & Porter LLP - Ashurst LLP - Baker & McKenzie LLP - Baker Botts LLP - Bracewell LLP - Bredin Prat - Brown Rudnick LLP - Bryan Cave LLP - Cadwalader, Wickersham & Taft LLP - Cahill Gordon & Reindel LLP - Chadbourne & Parke LLP - Cleary Gottlieb Steen & Hamilton LLP - Clifford Chance LLP - Cooley LLP - Covington & Burling LLP - Cuatrecasas, Gonçalves Pereira - Davis Polk & Wardwell LLP - De Brauw Blackstone Westbroek - De Pardieu Brocas Maffei - Debevoise & Plimpton LLP - Dechert LLP - DLA Piper - Eversheds LLP - Faegre Baker Daniels - Freshfields Bruckhaus Deringer - Fried, Frank, Harris, Shriver & Jacobson LLP - Gibson, Dunn & Crutcher LLP - Gide Loyrette Nouel - Gleiss Lutz - Graf & Pitkowitz Rechtsanwälte GmbH - Greenberg Traurig LLP - Hammonds LLP - Hengeler Mueller Partnerschaft & von Rechtsanwalte - Herbert Smith Freehills - Higgs & Johnson - Hogan Lovells LLP - Houthoff Buruma - Hughes Hubbard & Reed LLP - Hunton & Williams LLP - J&A Garrigues, S.L.P. - Jones Day - K&L Gates LLP - Keller Rohrback L.L.P. - Kelley Drye & Warren LLP - King & Spalding - Kirkland & Ellis LLP - Knobbe Martens - KPMG LLP - Kramer Levin Naftalis & Frankel LLP - Lang & Rahmann Rechtsanwalte - Latham & Watkins LLP - Linklaters - Locke Lord Edwards - Loyens & Loeff - Luther Rechtsanwaltsgesellschaft mbH - Maples and Calder - Mayer Brown LLP - McDermott Will & Emery LLP - McGuireWoods LLP - Milbank, Tweed, Hadley & McCloy LLP - Morrison & Foerster LLP - Mourant Ozannes - Norton Rose Fulbright LLP - O'Melveny & Myers LLP - Orrick, Herrington & Sutcliffe LLP - Paul Hastings LLP - Paul, Weiss, Rifkind, Wharton & Garrison LLP - Proskauer Rose LLP - Quinn Emanuel Urquhart & Sullivan, LLP - Reed Smith LLP - Ropes & Gray LLP - Schellenberg Wittmer - Schoenherr Rechtsanwaelte - Schultze & Braun - Sedgwick LLP - Seyfarth Shaw LLP - Shearman & Sterling LLP - Sidley Austin LLP - Simpson Thacher & Bartlett LLP - Skadden, Arps, Slate, Meagher & Flom LLP - Slaughter and May - Squire Patton Boggs - Sullivan & Cromwell LLP - Taylor Wessing LLP - Thierhoff Muller & Partner - Thompson & Knight LLP - Vinson & Elkins LLP - Walder Wyss & Partners - Walkers - Weil, Gotshal & Manges LLP - White & Case LLP - Willkie Farr & Gallagher LLP - Wilmer Cutler Pickering Hale and Dorr LLP For more information about this report visit http://www.researchandmarkets.com/research/5jg9mr/2017_eu_attorney


Dublin, March 02, 2017 (GLOBE NEWSWIRE) -- Research and Markets has announced the addition of the "2017 EU Attorney Rate Report" report to their offering. The 2017 European Union Attorney Hourly Rate Report details the hourly rates charged by Attorneys (Senior Partners, Partners, Counsel, Senior Associates and Associates) from 2011 - 2016 + 2017 Forecast at over 100 individual Law Firms practicing in the 28 Country Union with Germany, the UK and Belgium being the legal engines of growth. The Report has 9 Sections: 1. Overall Rates by Individual Firm, Practice and City 2. Overall Rates by City Consolidated 3. Rates by Industry Consolidated 4. Rates by AMLAW Group (10, 50, 100, 101-200 + Non-AMLAW US Firms) 5. Rates by AMLAW Group by Practice 6. Rates by AMLAW Group by City 7. Rates by AMLAW Group by Industry 8. Overall Rates Magic Circle Firms 9. Rates by Magic Circle Firms Individually 10. Rates by Magic Circle Firms Consolidated by Practice Area The EU economic recovery started much later than that in the United States so growth will continue in 2017 - industrial production is flat, unemployment is down, inflation is flat versus one year ago - as will levels of corporate legal spend and hourly rates charged by EU Attorneys. However, as the threat of a recession in the US grows due to slow economic growth and government debt, the EU faces uncertainty with the BREXIT vote and the highest level of government debt ever (85% of GDP Overall), according to the Report. Key Topics Covered: 1. Overall Rates by Individual Firm, Practice and City 2) Overall Rates by City Consolidated 3. Rates by Industry Consolidated 4. Rates by AMLAW Group (10, 50, 100, 101-200 + Non-AMLAW US Firms) 5. Rates by AMLAW Group by Practice 6) Rates by AMLAW Group by City 7. Rates by AMLAW Group by Industry 8. Overall Rates Magic Circle Firms 9. Rates by Magic Circle Firms Individually 10. Rates by Magic Circle Firms Consolidated by Practice Area Companies Mentioned - Addleshaw Goddard LLP - ADVISES Partnerschaft von Rechtsanwälten, Wirtschaftsprüfern und Steuerberatern - Akin Gump Strauss Hauer & Feld LLP - Allen & Overy LLP - Arnold & Porter LLP - Ashurst LLP - Baker & McKenzie LLP - Baker Botts LLP - Bracewell LLP - Bredin Prat - Brown Rudnick LLP - Bryan Cave LLP - Cadwalader, Wickersham & Taft LLP - Cahill Gordon & Reindel LLP - Chadbourne & Parke LLP - Cleary Gottlieb Steen & Hamilton LLP - Clifford Chance LLP - Cooley LLP - Covington & Burling LLP - Cuatrecasas, Gonçalves Pereira - Davis Polk & Wardwell LLP - De Brauw Blackstone Westbroek - De Pardieu Brocas Maffei - Debevoise & Plimpton LLP - Dechert LLP - DLA Piper - Eversheds LLP - Faegre Baker Daniels - Freshfields Bruckhaus Deringer - Fried, Frank, Harris, Shriver & Jacobson LLP - Gibson, Dunn & Crutcher LLP - Gide Loyrette Nouel - Gleiss Lutz - Graf & Pitkowitz Rechtsanwälte GmbH - Greenberg Traurig LLP - Hammonds LLP - Hengeler Mueller Partnerschaft & von Rechtsanwalte - Herbert Smith Freehills - Higgs & Johnson - Hogan Lovells LLP - Houthoff Buruma - Hughes Hubbard & Reed LLP - Hunton & Williams LLP - J&A Garrigues, S.L.P. - Jones Day - K&L Gates LLP - Keller Rohrback L.L.P. - Kelley Drye & Warren LLP - King & Spalding - Kirkland & Ellis LLP - Knobbe Martens - KPMG LLP - Kramer Levin Naftalis & Frankel LLP - Lang & Rahmann Rechtsanwalte - Latham & Watkins LLP - Linklaters - Locke Lord Edwards - Loyens & Loeff - Luther Rechtsanwaltsgesellschaft mbH - Maples and Calder - Mayer Brown LLP - McDermott Will & Emery LLP - McGuireWoods LLP - Milbank, Tweed, Hadley & McCloy LLP - Morrison & Foerster LLP - Mourant Ozannes - Norton Rose Fulbright LLP - O'Melveny & Myers LLP - Orrick, Herrington & Sutcliffe LLP - Paul Hastings LLP - Paul, Weiss, Rifkind, Wharton & Garrison LLP - Proskauer Rose LLP - Quinn Emanuel Urquhart & Sullivan, LLP - Reed Smith LLP - Ropes & Gray LLP - Schellenberg Wittmer - Schoenherr Rechtsanwaelte - Schultze & Braun - Sedgwick LLP - Seyfarth Shaw LLP - Shearman & Sterling LLP - Sidley Austin LLP - Simpson Thacher & Bartlett LLP - Skadden, Arps, Slate, Meagher & Flom LLP - Slaughter and May - Squire Patton Boggs - Sullivan & Cromwell LLP - Taylor Wessing LLP - Thierhoff Muller & Partner - Thompson & Knight LLP - Vinson & Elkins LLP - Walder Wyss & Partners - Walkers - Weil, Gotshal & Manges LLP - White & Case LLP - Willkie Farr & Gallagher LLP - Wilmer Cutler Pickering Hale and Dorr LLP For more information about this report visit http://www.researchandmarkets.com/research/5jg9mr/2017_eu_attorney


News Article | October 29, 2016
Site: www.prnewswire.co.uk

UPPDATERING OM IMPLEMENTERINGEN AV STRATEGISKA INITIATIV I STORBRITANNIEN The Intertain Group Limited ("Intertain") (TSX:IT), världens största bingoledda operatör på nätet, meddelade idag att man har fått långivarens samtycke som krävs för att ändra sina befintliga lånevillkor för att möjliggöra den lagstadgade planen för överenskommelsen ("Överenskommelsen") som ska underlätta implementeringen av Intertains omfattande  Storbritannien-centrerade strategiska initiativ ("Strategiska initiativ i Storbritannien"). Initiativen är avsedda att stärka värdet för aktieägarna och samtycke förväntas träda i kraft i dag under vissa villkor. De strategiska initiativen i Storbritannien omfattar den föreslagna börsnoteringen i London av det nyligen inkorporerade företaget i Storbritannien med huvudkontor i London, Jackpotjoy plc ("Jackpotjoy"), som avses bli moderföretag för Intertain group enligt överenskommelsen. Intertain fortsätter sitt arbete i samband med att Jackpotjoys stamaktier avses bli tillåtna på standardlistsegmentet på FCA:s officiella lista (UK Financial Conduct Authority) och för handel på Londonbörsens huvudmarknad för noterade värdepapper ("Börsnoteringen i London").Som tidigare meddelats förväntar sig Intertain att offentliggöra datum för när  överenskommelsen träder i kraft ("Ikraftträdandedatum") och sista datum som aktieägarna kan välja att få utbytbara aktier under överenskommelsen, minst fem arbetsdagar före ikraftträdandedatum eller sista datum för valet, beroende på vilket som inträffar först. För att underlätta genomförandet av överenskommelsen och börsnoteringen i London meddelade Intertain också att man räknar med att delårsrapporten för kvartalet som avslutades 30 september 2016 ska publiceras den 14 november 2016. Tillhörande samtal om resultat väntas hållas på morgonen den 15 november 2016. Aktieägare med frågor kring de strategiska initiativen i Storbritannien, överenskommelsen eller som önskar hjälp med att genomföra sitt val för att få utbytbara aktier enligt överenskommelsen, uppmanas kontakta Kingsdale Shareholder Services på: 1 866 581 1513 (avgiftsfritt i Nordamerika), genom att ringa betalsamtal på 1 416 867 2272 (utanför Nordamerika) eller via e-post till contactus@kingsdaleshareholder.com. Canaccord Genuity Corp. agerar som enda finansiella rådgivare i samband med implementeringen av de brittiska strategiska initiativen, bland annat börsnoteringen i London. Osler, Hoskin & Harcourt LLP agerar ombud för specialkommittén. Cassels Brock & Blackwell och Clifford Chance LLP agerar båda som kanadensiska och amerikanska/brittiska ombud för Intertain i samband med de brittiska strategiska initiativen. Kingsdale Shareholder Services agerar strategisk rådgivare och kommunikationsrådgivare åt Intertain. Intertain är ett onlinespelbolag som tillhandahåller underhållning till en global kundbas. Intertain erbjuder för närvarande bingoledda spel och kasinospel till sina kunder via sina varumärken InterCasino (http://www.intercasino.com), Costa (http://www.costabingo.com), Vera&John (http://www.verajohn.com), Jackpotjoy (http://www.jackpotjoy.com), Starspins (http://www.starspins.com) och Botemania (http://www.botemania.es). Mer information om Intertain finns på http://www.Intertain.com. DEN HÄR VERSIONEN OCH DESS INNEHÅLL ÄR INTE TILL FÖR UTGIVNING OCH FÅR INTE OFFENTLIGGÖRAS ELLER DISTRIBUERAS, I SIN HELHET ELLER DELVIS, DIREKT ELLER INDIREKT, I ELLER TILL ELLER FRÅN AUSTRALIEN, JAPAN ELLER NÅGON ANNAN JURISDIKTION DÄR SÅDAN DISTRIBUTION SKULLE VARA OLAGLIG ELLER SOM SKULLE KRÄVA REGISTRERING ELLER TILLSTÅND INOM SÅDAN JURISDIKTION ELLER TILL NÅGON ANNAN PERSON. Aktierna (inklusive de utbytbara aktierna) väntas bli utgivna till följd av att överenskommelsen inte har och inte kommer att bli registrerad enligt den amerikanska lagen om värdepappersmarknaden från 1933, i dess ändrade lydelse ("den amerikanska lagen om värdepappersmarknaden"), eller andra värdepapperslagar, och aktierna (inklusive de utbytbara aktierna) som utges i överenskommelsen väntas bli utgivna efter undantag från dessa registreringskrav enligt sektion 3(a)(10) i amerikanska lagen om värdepappersmarknaden och tillämpbara undantag under statliga värdepapperslagar. Detta pressmeddelande utgör inte ett säljerbjudande eller en uppmaning om ett erbjudande att köpa värdepapper. Det här meddelandet innehåller viss information och vissa uttalanden som kan utgöra "framåtriktad information" i den mening som avses i kanadensiska värdepapperslagar.  Ofta, men inte alltid, kan framåtriktad information identifieras genom användning av ord som "förväntar", "avser" och "förutser" eller negationer av sådana ord eller andra variationer eller synonymer för sådana ord, eller att man anger att vissa åtgärder, händelser eller resultat "kan" eller "kommer" att tas, förekomma eller uppnås. Framåtriktad information innefattar kända och okända risker, osäkerheter och andra faktorer som kan leda till att faktiska resultat, prestationer, framgångar eller utveckling i betydande grad avviker från dem som förutsågs av Intertain och som uttrycks eller antyds i den framåtriktade informationen. Framåtriktad information som finns i detta pressmeddelande innefattar, men är inte begränsat till, uttalanden rörande: (i) driften, verksamheten, ekonomiskt skick, förväntade ekonomiska resultat, prestanda, värdering, framtidsutsikter, möjligheter, prioriteringar, mål, pågående målsättningar, strategier och synen på Intertain; (ii) de strategiska initiativen i Storbritannien, inklusive potentiella resultat av dem och deras förmåga att stärka värdet för aktieägarna; (iii) Intertains förmåga att implementera inträdet på Londonbörsen (inklusive tillträdet av Jackpotjoys stamaktier på FCA:listan);(iv) möjligheten för den föreslagna överenskommelsen att underlätta implementeringen av de brittiska strategiska initiativen; (v) ikraftträdandedatum för långivarens samtycke under befintliga lånevillkor i samband med överenskommelsen och den tid inom vilken de återstående villkoren kommer att uppfyllas; (vi) vissa frågor rörande den föreslagna överenskommelsen och de strategiska initiativen i Storbritannien; (vii) Intertains avsikt att tillkännage ikraftträdandet och sista dag för valet minst fem arbetsdagar före den aktuella dagen; och (viii) Intertains avsikt att delårsrapporten för kvartalet som slutade 30 september 2016 ska publiceras den 14 november 2016 (och tidpunkten för relaterat resultatsamtal). Dessa uttalanden speglar Intertains nuvarande förväntningar avseende framtida händelser eller framtida resultat, prestationer, framgångar, utveckling, åtgärder och framtida trender som påverkar Intertain. Alla sådana uttalanden, utom uttalanden rörande historiska fakta, är framåtsyftande information. Sådan framåtriktad information baseras på ett antal antaganden som kan visa sig vara felaktiga, inklusive men inte begränsat till, att Intertains riskfaktorer (enligt definitionen nedan) inte leder till att faktiska resultat, prestationer, framgångar eller utveckling skiljer sig väsentligt från dem som beskrivs i den framåtriktade informationen. Sådan framåtriktad information skulle också kunna påverkas i hög grad av risker inklusive, men inte begränsade till: (i) godkännande från FCA, TSX och andra myndigheter och/eller att de övriga villkoren för att fullföljande ska vara uppfyllda eller upphävda på villkor som är tillfredsställande för Intertain eller överhuvudtaget och/eller att Intertain inte kan få en del av eller alla de förmåner man förväntar sig att få som resultat av implementeringen av de strategiska initiativen i Storbritannien (inklusive börsnoteringen i London) i sin helhet eller delvis; (ii) att kostnaderna för ledningens tid och pengar negativt kan påverka Intertains verksamhet; och (iii) att svängningar på marknaden eller förändringar i Intertains aktiepris inte påverkar Intertains förmåga att implementera de strategiska initiativen i Storbritannien och (iv) att villkoren för långivarnas medgivande i enlighet med Intertains befintliga lånevillkor träder i kraft på det sätt och under de tidsramar som förutsetts av Intertain eller överhuvudtaget. De föregående riskfaktorerna är inte avsedda att representera en komplett lista över faktorer som kan påverka Intertain. Ytterligare riskfaktorer diskuteras i Intertains årliga formulär från den 30 mars 2016 samt i Cirkuläret  om informationshantering daterat den 19 augusti 2016 under rubriken "Riskfaktorer". Alla sådana riskfaktorer kallas kollektivt "Intertains riskfaktorer". Även om Intertain har försökt att identifiera viktiga faktorer som kan orsaka att faktiska resultat, prestationer, framgångar eller utveckling skiljer sig väsentligt från de som beskrivs i den framåtriktade informationen, kan det finnas andra faktorer som orsakar att faktiska resultat, prestationer, framgångar eller utveckling inte blir som förväntat, beräknat eller avsett. Det finns inga garantier för att framåtriktad information kommer att visa sig vara korrekt, eftersom faktiska resultat, prestationer, framgångar eller utveckling sannolikt kommer att skilja sig, och kan skilja sig väsentligt, från dem som uttrycks i eller antyds i den framåtriktade informationen i detta meddelande. Läsare bör således inte förlita sig på framåtriktad information. Även om efterföljande händelser och utveckling kan leda till att Intertains förväntningar, beräkningar och synpunkter ändras, åtar sig Intertain inte och har inte någon skyldighet att uppdatera eller revidera någon framåtriktad information, förutom i enlighet med tillämpliga värdepapperslagar. Den framåtriktade informationen i detta meddelande får inte åberopas som att det presenterar Intertains förväntningar, beräkningar och synpunkter vid någon tidpunkt efter datumet för detta meddelande. All framåtriktad information i detta meddelande omfattas uttryckligen av denna varning.


News Article | December 7, 2016
Site: www.businesswire.com

FRAMINGHAM, Mass. & NEW YORK--(BUSINESS WIRE)--Staples, Inc. (NASDAQ:SPLS) and Cerberus Capital Management, L.P. (Cerberus) announced today that Staples and Cerberus have entered into an agreement in relation to the sale of a controlling interest in Staples’ European operations to a Cerberus affiliate. Staples’ European business consists of retail, contract, and online businesses in 16 countries generating aggregate annual sales of approximately €1.7 billion. Staples is retaining a 15 percent equity interest in the business and will be represented on its board of directors following the closing of the transaction. In accordance with applicable law, Staples will now consult relevant European works councils. Subject to these consultations and satisfaction of other conditions, the parties anticipate closing the transaction during the first quarter of Staples’ fiscal 2017 year. “One of our top strategic priorities has been to narrow our geographic focus on North America, and this is an important step toward simplifying our operations and better positioning Staples for sustainable long-term growth,” said Shira Goodman, Chief Executive Officer and President, Staples, Inc. “We believe that working with Cerberus will help enable the future success of the Staples Europe business, benefiting our associates and customers in the region.” “We intend to instill a keen sense of urgency, focus, and commitment throughout the entire Staples Europe organization, enhance the company’s competitive position across its markets and channels, and return the business to growth by capitalizing on its many assets, including its well-recognized brands, strong customer relationships, dedicated sales force, advanced distribution and IT infrastructure, comprehensive pan-European footprint, and talented management and associates,” said Steven F. Mayer, Co-Head of Global Private Equity and Senior Managing Director of Cerberus. “Our strategy is to invest in a variety of initiatives designed to strengthen Staples Europe’s position as the leading provider of solutions to small, mid-sized, and large businesses in Europe, including sales force expansion, further diversification of products and services beyond office supplies, and next-generation technologies. Our unrelenting focus throughout the organization will be on satisfying our customers and on operational execution.” Upon closing of the transaction, the Staples Europe business will be separated into a privately-held company controlled by an affiliate of Cerberus. The new company will enter into a licensing agreement with Staples for the use of certain Staples intellectual property, including its brand, a global accounts agreement, and transition services agreement governing a variety of services for defined periods. The company will operate under the Staples banner name and other sub-brands in European markets, and its associates will continue to be employees of Staples Europe, which will maintain its headquarters in Amsterdam. Olof Persson, an executive with Cerberus’ operations team and the former President and CEO of Volvo Group, will be appointed executive chairman of the new company. The agreement with Cerberus follows Staples’ recent announcement of the sale of its UK retail business to Hilco Capital Limited, which also aligned with Staples’ new strategic direction of right-sizing its international business. Barclays is acting as exclusive financial advisor to Staples. Clifford Chance LLP is acting as legal advisor to Staples. Kirkland & Ellis LLP and Linklaters LLP are acting as legal advisors to Cerberus. Staples helps small business customers make more happen by providing a broad assortment of products, expanded business services and easy ways to shop – in stores, online via mobile or through social apps. Staples Business Advantage, the business-to-business division, caters to mid-market, commercial and enterprise-sized customers by offering a one-source solution for the products and services they need, combined with best-in-class customer service, competitive pricing and a state-of-the-art ecommerce site. Headquartered outside of Boston, Staples, Inc. operates throughout North and South America, Europe, Asia, Australia and New Zealand. More information about Staples (NASDAQ: SPLS) is available at www.staples.com. Established in 1992, Cerberus Capital Management, L.P. is one of the world’s leading private investment firms. Cerberus has more than US $30 billion under management invested in four primary strategies: operational private equity, both control and non-control; distressed securities and assets; commercial mid-market lending; and real estate-related investments. From its headquarters in New York City and network of affiliate and advisory offices in the U.S., Europe and Asia, Cerberus has the on-the-ground presence to invest in multiple sectors, through multiple investment strategies, in countries around the world.


News Article | November 3, 2016
Site: www.realwire.com

LONDON – Thursday 3 November 2016 – International Law firm Clifford Chance LLP is working with Neota Logic Ltd, providers of intelligent software for legal and compliance, to develop automated solutions for assessing the impacts of regulatory rule changes on financial institutions. Initially, Neota and Clifford Chance are creating an application which is to generate shareable legal guidance in the highly regulated Over The Counter (OTC) Derivatives market. Paul Greenwood, Clifford Chance Chief Information Officer, said: "We are constantly exploring ways in which we can apply new technologies to the benefit of our lawyers and their clients and have made several recent investments in this area. Neota Logic is an example of how combining our expertise with intelligent automation software can add significant value. This collaboration is part of our journey to bring together the best of today's technological capabilities and the best legal skills and expertise." Richard Seabrook, European Managing Director, Neota Logic, added: "We are hugely excited to be working with such a prestigious firm as Clifford Chance. Our unique technology is ideal for automating complex, regulatory compliance matters. Through our intelligent applications, lawyers and their clients can quickly get a sense of how the rules may apply to their unique business situation and what steps they need to take." About Neota Logic Neota Logic is a global provider of artificial intelligence software for legal and compliance. Combining reasoning, workflow and intelligent document assembly, the company’s easy-to-develop, intelligent advisors help law firms and their clients improve efficiency, manage risk and achieve regulatory compliance. For more information, visit http://www.neotalogic.com. About Clifford Chance LLP Clifford Chance is one of the world's pre-eminent law firms with significant depth and range of resources across five continents. As a single, fully integrated, global partnership, we pride ourselves on our approachable, collegiate and team based way of working. We always strive to exceed the expectations of our clients, which include corporates from all the commercial and industrial sectors, governments, regulators, trade bodies and not for profit organisations. We provide them with the highest quality advice and legal insight, which combines the firm's global standards with in-depth local expertise.

Loading Clifford Chance LLP collaborators
Loading Clifford Chance LLP collaborators